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The Influence of Energy Depletion 
by Metformin or Hypocaloric 
Diet on Thyroid Iodine Uptake in 
Healthy Volunteers: a Randomized 
Trial
Yvette J. E. Sloot  1, Marcel J. R. Janssen2, Antonius E. van Herwaarden3, Robin P. Peeters4, 
Romana T. Netea-Maier1 & Johannes W. A. Smit1
Sufficient thyroid iodine uptake is needed to ensure effective radioactive iodine (RAI) treatment, which 
is mediated by the sodium-iodide symporter (NIS). Activation of AMP-activated-protein-kinase (AMPK), 
leads to decreased NIS expression and thyroid iodine uptake in in vitro and animal models. Clinically 
relevant conditions that lead to AMPK activation include metformin use and hypocaloric conditions. 
Here, we aim to assess the effects of metformin and hypocaloric diet on thyroid iodine uptake in 
healthy volunteers. Healthy male volunteers were included and randomized. Group 1 (n = 8) received 
metformin, group 2 (n = 7) followed a hypocaloric diet (1500 kcal/day), superposed on a moderate iodine 
restriction diet; Baseline measurements included thyroid iodine-123 (I-123) uptake and TSH, fT4, T3 and 
rT3 levels. After two weeks, thyroid function and I-123 uptake measurements were repeated. Baseline 
characteristics were similar between groups. Levels of TSH and fT4 were similar after each intervention. 
T3 decreased after hypocaloric diet and metformin (−0.2 ± 0.19 nmol/L, p = 0.0327; respectively 
−0.13 ± 0.13 nmol/L, p = 0.0282), resulting in decreased T3/rT3 ratios. There was no significant 
difference in thyroid I-123 uptake after each intervention. In conclusion, metformin treatment and 
hypocaloric diet resulted in a significant decrease in T3 levels and T3/rT3 ratios in healthy volunteers, 
without significant effects on thyroid iodine uptake. We found no indications that metformin or 
hypocaloric diet will have clinically relevant effects on RAI uptake.
Treatment with radioactive iodine (RAI) is a widely used and highly efficient treatment for benign thyroid dis-
eases and differentiated thyroid carcinoma (DTC)1,2. To improve RAI treatment efficacy and reduce potential side 
effects, it is important to identify factors that influence thyroid RAI uptake.
The specific thyroid iodine uptake is mediated by the sodium iodide symporter (NIS)3. The main regulator 
of NIS expression is thyroid stimulating hormone (TSH), but other regulatory pathways have been described 
as well4,5. Previous research has shown that activation of the master sensor for energy depletion, 5′ adenosine 
monophosphate-activated-protein-kinase (AMPK), leads to decreased NIS expression and iodine uptake in in 
vitro studies and animal models6–8. Conditions that deplete cellular energy stores induce activation of AMPK, 
which leads to downregulation of energy consuming processes and upregulation of adenosine triphosphate 
(ATP)-producing pathways in order to restore the cell’s energy balance9.
In rat thyroid cell lines and in animal studies, activation of AMPK using metformin or 
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) significantly reduced NIS expression and iodine 
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uptake through reduced transcription and increased degradation of NIS6–8. These results show that modulation 
of AMPK activity influences NIS expression and RAI uptake.
Metformin is a first-choice drug in type 2 diabetes mellitus (DM)10 and a well-known pharmacological mod-
ulator of AMPK11. Metformin is being investigated as adjunct in the treatment of DTC12, as its use has been 
associated with beneficial effects on DTC in preclinical and patient studies13–15. However, metformin has also 
been shown to activate AMPK leading to reduced NIS expression in vitro and in animal models6. Metformin may 
therefore reduce RAI therapy efficacy.
Reduced caloric intake also leads to AMPK activation, and could thus also result in reduced NIS expres-
sion and RAI uptake9. Preparation for RAI treatment in DTC consists of either thyroid hormone withdrawal for 
3–4 weeks or administration of recombinant human TSH (rhTSH) in order to stimulate thyroid iodine uptake2. 
Thyroid hormone withdrawal is associated with symptomatic hypothyroidism and reduced caloric intake due 
to appetite loss, fatigue, weight changes, gastro-intestinal complaints and depression16,17. In addition, an iodine 
depleted diet which is often used in preparation for RAI therapy, is also accompanied by decreased appetite and 
caloric intake18.
Energy depletion by metformin and hypocaloric conditions are thus clinically relevant conditions that lead to 
AMPK activation, and we hypothesize that these could result in reduced thyroid iodine uptake. Therefore, in this 
study we aim to assess the physiological effects of energy depletion by metformin and hypocaloric diet on thyroid 
iodine uptake in healthy volunteers.
Results
Baseline characteristics. A total of 29 volunteers were screened and had provided signed informed con-
sent. Nine subjects withdrew before the start of the study. One subject started with the study but was not able 
to comply with the iodine restriction and left the study. For our analysis, we included a total of 19 healthy male 
volunteers between the ages of 19 and 43 years, who completed the study, with a mean age of 24.7 ± 5.5 years. 
Baseline parameters (Table 1) were comparable between the two intervention groups, with exception of a slightly 
higher self-reported daily energy intake in the hypocaloric diet group (3082 ± 390 kcal/day), compared to the 
metformin group (2404 ± 305 kcal/day, p = 0.008).
Subjects were compliant with the dietary restrictions of the hypocaloric diet. Mean total weight loss after 
intervention was 1.8 ± 2.4 kg in the diet group, and 0.8 ± 1.4 kg for the metformin group. BMI in the diet group 
decreased from 22.8 ± 2.4 kg/m2 to 22.2 ± 2.3 kg/m2 (p = 0.077), whereas the decrease in the metformin group 
was 0.2 ± 0.4 kg/m2, see Supplementary Table 2.
Iodine excretion before interventions demonstrated the adherence of the participants to the low iodine diet. 
No significant differences were found in urinary iodine excretion between baseline and post intervention meas-
urements (Supplementary Table 2).
Compliance to metformin was high; two subjects forgot one dose of metformin once. Apart from minor 
gastro-intestinal side effects, no major side effects of metformin were reported.
Effect of metformin and hypocaloric dieting on TSH and thyroid hormone levels. Levels of 
s-TSH, s-fT4, s-T3 and s-rT3 at baseline and after each intervention are depicted in Fig. 1. There were no signif-
icant differences in s-TSH levels and s-fT4 levels before and after each intervention within each group, indicat-
ing that hypocaloric dieting or metformin did not affect TSH or fT4 levels. Serum levels of TSH and fT4 were 
also similar between the groups at baseline or after intervention. Interestingly, hypocaloric dieting and met-
formin lead to a significant decrease in s-T3 levels within the normal range, with a reduction of 0.2 ± 0.19 nmol/L 
(p = 0.033), respectively 0.13 ± 0.13 nmol/L (p = 0.028). The T3/fT4 ratio decreased after hypocaloric dieting from 
0.134 ± 0.035 to 0.119 ± 0.020, and was significantly reduced after metformin use from 0.125 ± 0.015 at baseline 
to 0.114 ± 0.019 (p = 0.015) post intervention. In addition, s-rT3 increased after two weeks of hypocaloric diet 
Total Diet Metformin
n = 19 n = 7 n = 8
Age 24.7 (5.5) 24.7 (2.6) 26.3 (7.9)
Height (m) 1.8 (0.1) 1.9 (0.1) 1.8 (0.1)
Weight (kg) 76.6 (8.7) 79.1 (11.7) 73.7 (6.9)
BMI (kg/m2) 22.9 (2.0) 22.8 (2.4) 22.6 (2.2)
Daily resting Energy Need (Kcal)§1 1805 (225) 1778 (352) 1793 (129)
Activity factor (PAL) 1.7 (0.1) 1.6 (0.2) 1.6 (0.1)
Total Energy Expenditure (Kcal)¶ 3006 (503) 2946 (748) 2931 (329)
Lean Body Mass (kg)† 57.6 (4.8) 59.6 (6.2) 55.9 (4.0)
Mean daily intake (Kcal) 2704 (466) 3082 (390)* 2404 (305)
Table 1. Baseline characteristics of the three intervention groups. Notes: Values are presented as 
mean ± S.D. *Comparison between hypocaloric diet group and metformin group p = 0.008; §Calculated 
with Harris and Benedict equation (ref.36 for men. Daily resting Energy Need = 88.362 + (13.398 × weight 
(kg)) + (4.799 × length (cm))− (5.677 × age). ¶Total Energy Expenditure = Resting energy need × PAL. 
†According to formula of Hume (ref.37). Lean body mass = (0.32810 × weight (kg)) + (0.33929 × length 
(cm))−29.5336.
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from 0.41 ± 0.10 nmol/L to 0.46 ± 0.10 nmol/L (p = 0.050), resulting in a significant decrease of the T3/rT3 ratio 
of 5.7 ± 1.5 at baseline vs. 4.5 ± 0.8 post intervention (p = 0.019). In the metformin group, a significant decrease 
of the T3/rT3 ratio from 5.0 ± 1.2 to 4.5 ± 1.3 was observed as well (p = 0.022).
In the 4 control subjects, baseline measurements were within the normal range. As expected, no significant 
differences were observed in s-TSH, s-fT4 levels, s-T3 and s-rT3 levels during the course of the study.
Effect of metformin and hypocaloric dieting on thyroid radioactive iodine uptake. To assess 
the effect of metformin use and hypocaloric dieting on thyroid iodine uptake, we measured thyroid I-123 uptake 
(Fig. 2A). There were no significant changes in I-123 uptake compared with baseline in any of the groups. In 
addition, I-123 uptake measurements were similar between groups, both at baseline and after intervention. We 
also calculated the percentage of change in I-123 uptake compared to baseline (Fig. 2B). There were no significant 
differences in percentage of change in I-123 uptake. These results indicate that hypocaloric dieting or metformin 
use did not result in significant changes in thyroid I-123 uptake in healthy volunteers.
Discussion
To our knowledge, this is the first study investigating the effects of energy depletion by metformine or hypocaloric 
diet, both important AMPK activators, on thyroid iodine uptake in humans. We showed that hypocaloric dieting 
or metformin lead to a significant decrease in s-T3 levels and a significantly decreased T3/rT3 ratio whereas thy-
roid iodine uptake was not influenced.
A decreased T3/rT3 ratio after hypocaloric dieting as observed in our study is in line with other studies in 
which low energy diets are associated with a reduced ratio of T3/rT319–23 by decreased deiodinase 2 (D2) and 
deiodinase 1 (D1) activity and an increase in deiodinase 3 activity (D3)19–21,24. Furthermore, selective carbohy-
drate deficiency specifically results in reduced peripheral conversion of T4 to T3 through reduced D2 activity20,22. 
Although prolonged weight loss has been associated with a reduction of s-TSH19,25,26, we did not observe signifi-
cant changes in TSH levels after hypocaloric dieting, which is likely due to the fact that the observed weight loss 
was only small and the time of intervention was short.
Interestingly, in the metformin group we also observed a significant reduction of s-T3 levels, a decreased 
T3/rT3 ratio, slightly elevated s-rT3 levels and unchanged s-TSH and s-fT4 levels. These results suggest that 
metformin influences peripheral deiodination as well, as the use of serum T3/rT3 and T3/T4 ratios are validated 
parameters for deiodinase activity27,28. In contrast to our findings, a study from Krysiak et al. (2018) showed that 
treatment with metformin for several months did not affect TSH, fT4 and T3 levels in euthyroid patients with 
type 2 diabetes29. Possible explanations could be the difference in study population, the dose of metformin and 
the duration of the study. Insulin resistance and type 2 diabetes is associated with type 2 thyroid allostatic load, 
Figure 1. Effects of hypocaloric dieting and metformin on serum TSH, fT4, T3, rT3, the T3/rT3 ratio and 
T3/fT4 ratio in healthy volunteers before and after intervention. Serum TSH levels were log transformed and 
differences before and after intervention were determined with paired student’s T tests. *P < 0.05: significant 
effect of interventions within groups when compared with baseline.
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e.g. higher levels of active thyroid hormone T3 due to upregulation of peripheral deiodinases and increased 
plasma protein binding30,31. In contrast, conditions in our study, e.g. energy depletion by hypocaloric dieting and 
short-term metformin use in healthy volunteers, are examples of type 1 thyroid allostasis, resulting in downreg-
ulation of active thyroid hormone synthesis. Type 1 thyroid allostasis is associated with low or normal TSH and 
fT4 levels and a reduction in T3, caused by a downregulation of D1 and D2 deiodinases and decreased plasma 
protein binding of thyroid hormones30. Further research is necessary to investigate the short and long-term effects 
of metformin on T3 levels and deiodinase activity.
Our hypothesis that energy depletion by hypocaloric diet or metformine leads to decreased iodine uptake was 
not confirmed by our study. We postulate that this is related to the unchanged TSH levels. Although we were not 
able to perform thyroid tissue AMPK measurements, previous research suggests that caloric restriction similar 
to our study and even for a duration of only five days, effectively results in increased AMPK activity in other 
tissues32. Likewise metformin treatment in a clinically relevant dose as used in our study, results in AMPK activa-
tion in vivo as well33. Thus, although the fact that we were not able to study thyroid tissue AMPK is an important 
limitation, we believe that short term energy depletion does not lead to significant alterations in thyroid iodine 
uptake as TSH is not affected.
Limitations of this study include the short duration and the fact we only included a relatively small number 
of subjects. The short duration of the study was chosen by purpose, as the clinical setting of radioiodine therapy 
preparation involves a preparatory phase of several weeks. Although prolonged energy depletion could have 
given different results, we believe that the current design is more relevant for the context of radioiodine therapy. 
With respect to the number of participants, the study had sufficient power to detect subtle changes in thyroid 
hormone levels. Furthermore, this study would have 80% power to pick up a mean difference of ≥8.0% in I-123 
uptake between baseline and post intervention, e.g. a mean reduction of ±26%. Indeed, previous in vivo studies 
in animals, showed a very large effect size with a reduction of thyroid I-uptake up to 35% after AICAR treatment 
as well7.
This mechanistic study was performed in healthy volunteers to enable unbiased analyses of study parameters. 
As aberrant AMPK activity, independent of energy availability, has also been associated with thyroid cancer34, 
we cannot extrapolate the study results to patients with benign thyroid disease and DTC. However, we believe 
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Figure 2. Effects of hypocaloric dieting and metformin on thyroid iodine-123 (I-123) uptake. Panel A shows 
the I-123 uptake at 4 hours, 24 hours and 48 hours after ingestion at baseline and after intervention. Panel B 
shows the percentage of change in I-123 uptake compared to baseline measurements at the three different time 
points for each intervention. Values are depicted as mean ± SEM.
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that the fact that a short course of energy depletion does not affect endogenous TSH and thyroid iodine uptake, 
is relevant for clinical practice.
In conclusion, two weeks of metformin use or hypocaloric dieting decreased serum T3/rT3 ratios, but did not 
lead to significant and negative effects on radioactive iodine uptake in healthy volunteers. This may be relevant for 
radioiodine therapy in patients with thyroid disorders.
Methods
Subjects. Healthy male volunteers were recruited by advertisements on the website and digital student 
forums of the Radboud University Medical Center Nijmegen, and handing out advertisement flyers on several 
locations in the vicinity of the hospital. Subjects were eligible to participate when they were aged between 18 and 
50 years, healthy and had no history of thyroid disease or renal insufficiency. Exclusion criteria included: body 
mass index (BMI) above 30 kg/m2, current smoker, structural alcohol intake >3 units/day, any acute or chronic 
illness including diabetes mellitus, inflammatory disease, cardiac or respiratory conditions, use of medication, use 
of supplements that contain large quantities of iodine, subjects who had undergone imaging studies using iodine 
containing contrast in the last three months, subjects who have taken part in any drug trial within two months 
prior to start of this study. Eligibility was verified by interview and laboratory testing for TSH and creatinine. The 
Medical Ethics Committee of the Radboud University Medical Center, Nijmegen, The Netherlands approved 
the study protocol, and all participants provided written informed consent. Experiments were conducted In the 
Radboud University Medical Center Nijmegen, The Netherlands between October 2016 and May 2017, in accord-
ance with the principles expressed in the Declaration of Helsinki. The trial was registered in the Dutch National 
Trial Register (NTR 5853, registered on 10 May, 2016).
Experimental design. Participants were randomly subjected to metformin or caloric restriction, super-
posed on a iodine restricted diet. A 4-weeks period with iodine restriction only served as reference. For this 
proof-of principle pilot study we aimed to include at least seven subjects per intervention group. Subjects who 
were enrolled after screening received a diary to register daily caloric intake and an estimate of physical activity 
factor (PAL) according to the Dutch Health Council guidelines35. Daily energy need was estimated using the 
Harris-Benedict equation36 for daily resting energy need. Total Energy Expenditure was calculated by multiplying 
daily resting energy need with the recorded PAL, and lean body mass using the equation described by Hume37. 
Subjects were instructed to follow iodine restriction two weeks prior to baseline measurements, until the end of 
the study. Supplementary Table 1 states the instructions for the iodine restriction.
After two weeks of iodine restriction, baseline measurements were performed. Blood was drawn to measure 
serum levels of TSH (s-TSH), free thyroxine (s-fT4), 3,5,3′ triiodothyronine (s-T3) and reverse triiodothyro-
nine (s-rT3). Subjects received 5 MBq of iodine-123 (I-123) orally, and 4, 24 and 48 hours after ingestion I-123 
uptake was measured with an uptake probe (thallium-doped sodium iodide (NaI (TL)) crystal (Unispec multi 
channel analyzer, Canberra Industries inc., CT, USA)). Thyroid I-123 uptake was calculated as percentage of 
total administered I-123 using the following formula: Uptake (%) = (Cthyroid − Cblanc)/(Ccalibration − Cbkg), with 
Cthyroid = number of counts over thyroid; Cblanc = number of counts measured at blanc; Ccalibration = number of 
counts administered, measured at the calibration source; Cbkg = number of counts measured at research location 
(background radiation).
Next, subjects were randomly assigned to the metformin or hypocaloric diet group using simple block rand-
omization by Y.S. Subjects assigned to the metformin group received metformin (Metformin HCL, Centrafarm 
B.V., Etten-Leur, The Netherlands) for two weeks, (starting with 500 mg/day, increasing up until 2000 mg/day in 
the last week). Subjects in the diet group received a meal plan for two weeks for a hypocaloric diet of ~1500 kil-
ocalories/day (an estimated caloric restriction of ~40%), with a high fat (50%), low carbohydrate (30%) content. 
After two weeks, measurements of serum TSH, fT4, T3, rT3, urinary iodine excretion and I-123 uptake were 
repeated. Additionally, four subjects continued the low iodine diet after the 2-weeks baseline period to verify 
influence of time on parameters. Primary outcome was defined as significant difference in thyroid I-123 uptake 
between baseline and post-intervention, whereas secondary outcomes were defined as changes in serum levels 
of TSH, fT4, T3, rT3 or T3/rT3 and T3/fT4 ratios. Each subject served as his own control. A flow chart for the 
experimental design of the study is depicted in Supplementary Fig. 1.
Adherence to the iodine restriction was checked at baseline and post intervention with a questionnaire, entries 
in the intake-diary and a morning spot urine sample. Adherence to the hypocaloric diet was checked by weight 
measurements and entries in the diary, whereas metformin use was checked by performing pill counts and check-
ing the diary.
Laboratory measurements. Levels of s-TSH were directly measured after blood withdrawal using a sand-
wich Electro Chemi Luminescence Immuno Assay (ECLIA) on a random-access assay system Modular Roche 
Diagnostic (Roche Diagnostics, Rotkreuz, Switzerland, reference interval 0.27–4.2  mU/L). s-fT4 and s-T3 levels 
were measured with a competitive Electro Chemi Luminescence Immuno Assay (ECLIA) on a random-access 
assay system (Roche Diagnostics), reference intervals for s-fT4 and s-T3: 10.0–23.0 pmol/L respectively 1.2–
3.1 nmol/L. s-rT3 were determined at a later time point in serum samples stored at −80 °C using an in-house 
Radioimmunoassay (RIA) at the Erasmus Medical Center Rotterdam, The Netherlands as previously described38. 
Morning urine was stored at −80 °C to measure urinary iodine excretion and creatinine after completion of the 
study as described previously39. Briefly, the urine iodine concentration was measured with the Sandell-Kolthoff 
reaction method, using a Peltier Thermal Cycler (PTC-200) for the heating and cooling process. The reference 
interval for urinary iodine excretion was 0.2–0.4 µmol/L. Serum and urinary creatinine concentration were 
measured by an enzymatic assay (Roche) on a Cobas C6000 anlyzer (Roche Diagnostics). Reference interval for 
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serum creatinine concentration was 60–110 µmol/L, the reference value for urinary creatinine concentrations 
was < 20 mmol/24 hours.
Statistics. Statistical analysis was performed by IBM SPSS statistics 22.0 software (NY, USA) and figures were 
made in Graphpad Prism 5 (CA, USA). Normality was tested using D’Agostino and Pearson omnibus normality 
test. Continuous variables are expressed as means ± standard error of mean (SEM)/standard deviation (SD) or 
median with interquartile range (IQR) as indicated in the figure legend. Values for s-TSH showed a skewed distri-
bution and were therefore log-transformed. Regarding I-123 uptake measurements, the percentage of change in 
I-123 uptake after intervention compared to baseline was calculated as well.
Analysis was performed per protocol. Differences before and after intervention within each group were 
analyzed using paired t-test for parametric variables, or the Wilcoxon matched-pairs signed rank test for 
non-parametric variables. Differences between the two groups were analyzed using two-tailed paired t-test for 
parametric variables, or the Wilcoxon matched-pairs signed rank test for non-parametric variables. The level of 
significance was defined as p-values below 0.05.
Data Availability
All data generated during and/or analyzed during the current study are available from the corresponding author 
on reasonable request.
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